Comparison of five point-of-care prothrombin and activated partial thromboplastin time devices based on age of blood sample
- PMID: 12395962
Comparison of five point-of-care prothrombin and activated partial thromboplastin time devices based on age of blood sample
Abstract
Delays in processing statium (STAT) blood samples have led to the production of an increasing number of point-of-care tests. Product inserts recommend measuring blood samples immediately after procurement, suggesting that delays may invalidate the test results. We studied the effect of the age of blood samples on point-of-care (POC) prothrombin time (PT) and an activated partial thromboplastin time (aPTT) result. Informed consent was obtained from 11 patients undergoing cardiopulmonary bypass (CPB). Blood samples (40 mL) were taken from each patient. Each blood sample was used to perform five PT tests and six aPTT tests on five POC devices (Gem PCL, Hemochron 801, Hemochron Jr. Signature, Hemochron Response, Rapidpoint Coag) at three different sample ages [< 60 s (fresh blood), 10 and 18 min after sample collection]. Blood samples were procured in a plastic syringe devoid of air bubbles, which was left undisturbed between tests but was gently agitated before initiating the 10- and 18-min tests. For tests requiring citrated whole blood, a fraction of each sample was anticoagulated (3.8% citrate) at each age. Statistical analysis was used for comparison of test results for fresh blood to aged samples (10 and 18 min). Test values were recorded as International Normalized Ratio (INR) and seconds for PT and aPTT, respectively. Two devices, the Hemochron 801 and Hemochron response showed statistically, although not clinically, significant variation in PT test results when the samples were aged to 10 and 18 minutes. As for aPTT results, Hemochron 801, Hemochron response, Hemochron Jr. signature, and Gem PCL showed statistically significant variation at 18 minutes. One device (Hemochron 801) reported results with 10-min aged blood that were statistically different from fresh blood. None of the aPTT tests results from any device produced results with aged blood that were clinically different from fresh blood. This study suggests that, in the tests evaluated, blood samples that have aged 10 or 18 min will produce clinically relevant aPTT and PT results, respectively.
Similar articles
-
How does the age of a blood sample affect it's activated clotting time? Comparison of eight different devices.J Extra Corpor Technol. 2002 Sep;34(3):175-7. J Extra Corpor Technol. 2002. PMID: 12395961
-
Electronic data management for the Hemochron Jr. Signature coagulation analyzer.J Extra Corpor Technol. 2002 Sep;34(3):182-4. J Extra Corpor Technol. 2002. PMID: 12395963
-
Limits of agreement between measures obtained from standard laboratory and the point-of-care device Hemochron Signature Elite(R) during acute haemorrhage.Br J Anaesth. 2014 Mar;112(3):514-20. doi: 10.1093/bja/aet384. Epub 2013 Dec 12. Br J Anaesth. 2014. PMID: 24335551
-
[Samples in Coagulation Test].Rinsho Byori. 2015 Dec;63(12):1397-404. Rinsho Byori. 2015. PMID: 27089656 Review. Japanese.
-
Activated Partial Thromboplastin Time and Prothrombin Time Mixing Studies: Current State of the Art.Semin Thromb Hemost. 2023 Sep;49(6):571-579. doi: 10.1055/s-0042-1756196. Epub 2022 Sep 2. Semin Thromb Hemost. 2023. PMID: 36055261 Review.
Cited by
-
Recognizing and Managing Breast Implant Complications: A Review for Healthcare Providers Who Treat Women Who Underwent Breast Implant-Based Surgery.Int J Womens Health. 2025 May 7;17:1297-1312. doi: 10.2147/IJWH.S501800. eCollection 2025. Int J Womens Health. 2025. PMID: 40357021 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Research Materials